Potential of Farnesyl Transferase Inhibitors in Combination Regimens in Squamous Cell Carcinomas

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Current treatments for recurrent and metastatic squamous cell carcinoma (SCC) have limited efficacy and poor outcomes.
• Understanding resistance mechanisms and identifying new therapeutic targets are crucial for improving patient survival.
• Head and neck squamous cell carcinoma (HNSCC) represents a significant unmet medical need.

Purpose of the Study:

• To explore the potential of tipifarnib, a farnesyl transferase inhibitor (FTI), as a therapeutic agent for SCC.
• To investigate tipifarnib's efficacy in genetically defined subsets of SCC, particularly those with HRAS mutations.
• To evaluate tipifarnib's role in combination therapies for SCC and other tumor types.

Main Methods:

• Clinical activity assessment of tipifarnib in SCC patients.
• Bioinformatic analyses to identify broader patient populations responsive to tipifarnib.
• Patient-derived xenograft modeling to study drug resistance mechanisms.
• In vitro studies to assess tipifarnib's impact on farnesylated proteins and resistance pathways.

Main Results:

• Tipifarnib demonstrated encouraging clinical activity in HNSCC with HRAS mutations.
• Evidence suggests HRAS pathway dependency in a broader SCC population when combined with agents like cisplatin, cetuximab, or alpelisib.
• Tipifarnib inactivates farnesylated proteins involved in resistance to various therapies, including immunotherapies.

Conclusions:

• Tipifarnib is a promising targeted therapy for a subset of SCCs, particularly those with HRAS alterations.
• Tipifarnib holds potential as a combination therapy backbone for SCC and potentially other cancers.
• Further research into tipifarnib-based combination regimens could lead to improved treatment strategies and patient outcomes.